It was widely reported yesterday, that the commonly used HbA1c test for diagnosing and monitoring Type 2 diabetes, has been found to potenti

Occuity enters Boehringer Ingelheim start-ups program Synapse Acceleration®, looking at non-invasive glucose monitoring in veterinary

By 2030, it is estimated that over five and a half million people in the UK will be living with diabetes. [1] And whilst Type 2 diabetes,...

Like us, they recognise that the healthcare challenges we’re looking to tackle are increasingly serious problems. What's more the...

Let’s be honest; some terms relating to our eyes may be more familiar than others. It might be easy to point to the cornea, the dome at...

Occuity are delighted to announce the successful raise of more than £1m. The raise will enable us to continue the development of novel...